Interferon alfa-2b Pregnancy and Breastfeeding Warnings
Interferon alfa-2b is also known as: Intron A
Interferon alfa-2b Pregnancy Warnings
Interferon alfa-2b has been assigned to a pregnancy category C by the FDA. When used with ribavirin, the combination therapy has been assigned to pregnancy category X by the FDA. Animal studies have revealed evidence of abortifacient effects. There are no controlled data in human pregnancy. Interferon alfa-2b is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.
A 26-year-old woman diagnosed with hepatitis C, at 16 weeks' gestation with twins, was successfully treated with a short-course (10 weeks) of interferon alfa-2b. The therapy was discontinued because of myalgia, excessive fatigue, and depressive symptoms. This patient received a total dose of 72 million units of interferon alfa. Follow-up exams of the infants, at 12 and 18 months of age, showed them doing well.
Interferon alfa-2b Breastfeeding Warnings
There are no data on the excretion of interferon alfa-2b into human milk. However, animal studies have revealed evidence of interferons being excreted into milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from interferon alfa-2b, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.